Last mentioned: Mar 26, 2026
FDA Modernization Act 2.0
President Biden signs legislation removing the requirement for animal testing for biosimilars and new drugs.
Hybrid Submission Standards
Expected formalization of regulatory pathways that prioritize NAM data over animal data for specific drug classes.
OOC Commercialization
Widespread adoption of organ-on-a-chip systems in early-stage pharmaceutical R&D for toxicity screening.
EU Regulatory Shift
The European Parliament and EMA accelerate roadmaps for the phase-out of animal use in regulatory testing.
The pharmaceutical industry is navigating a historic shift as the FDA Modernization Act 2.0 removes the mandate for animal testing in drug development. However, while technologies like organ-on-a-chip and AI offer higher human predictivity, they currently lack the systemic complexity required to fully replace animal models in late-stage safety assessments.
Traditional Chinese Medicine (TCM) is undergoing a digital transformation, utilizing AI-assisted acupuncture and digital pulse diagnosis to standardize ancient practices. Supported by China's 'Healthy China 2030' initiative and the 15th Five-Year Plan, these technological advancements aim to provide scientific evidence and global scalability for TCM across 196 countries.
A major breakthrough in artificial intelligence is transforming breast cancer research, enabling predictive screening and precision diagnostics. This technological shift is expected to significantly accelerate clinical trial timelines and improve patient outcomes through earlier intervention.
As market volatility persists in early 2026, Eli Lilly and Veeva Systems emerge as top growth picks driven by the obesity drug boom and AI integration. With Eli Lilly's tirzepatide securing its spot as the world's top-selling drug and new oral GLP-1s on the horizon, the pharmaceutical landscape is shifting toward tech-heavy, high-margin innovation.
Researchers at Lamont-Doherty Earth Observatory have utilized advanced AI to document a significant global increase in floating macroalgae over the past decade. This discovery, powered by machine learning analysis of satellite imagery, highlights the growing role of 'Blue Biotech' in identifying new biological resources for pharmaceutical and industrial applications.
A new study reveals a growing disconnect between individual researcher efficiency and systemic scientific progress. While AI tools significantly reduce the time required for data processing and manuscript preparation, they have yet to demonstrate a measurable impact on the rate of foundational breakthroughs.
At the India AI Impact Summit 2026, Minister Ashwini Vaishnaw highlighted a growing global consensus on mitigating AI risks while prioritizing healthcare as a core sector for AI deployment. This shift signals a move toward impact-driven, regulated AI applications that could transform drug discovery and diagnostics.
Researchers at St. Jude Children’s Research Hospital have developed M-PACT, an artificial intelligence tool that classifies pediatric brain tumors using liquid biopsy data. By analyzing DNA methylation patterns in cerebrospinal fluid, the tool offers a minimally invasive alternative to traditional surgical biopsies.
Researchers at UC San Diego have developed an artificial intelligence model that accurately predicts the risk of colorectal cancer in ulcerative colitis patients with low-grade dysplasia. This digital pathology tool addresses a critical clinical gap by identifying which patients require aggressive intervention versus those who can safely remain under surveillance.
This page surfaces every story mentioning Artificial Intelligence across our biotech coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running biotech beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Artificial Intelligence was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |